Mirum Pharmaceuticals, Inc. (MIRM) Return on equity 2020–2025
Mirum Pharmaceuticals, Inc. (MIRM) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-7.4%FY2025 · since FY2020: -60.0% → -7.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -7.4% | +31.6 pp |
| FY2024 | -39.0% | +26.7 pp |
| FY2023 | -65.7% | +29.8 pp |
| FY2022 | -95.5% | -25.6 pp |
| FY2021 | -69.9% | -9.9 pp |
| FY2020 | -60.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More MIRM financial trends
MIRM RevenueMIRM Net incomeMIRM Net marginMIRM Gross profitMIRM Gross marginMIRM Operating incomeMIRM Operating marginMIRM Operating cash flowMIRM Free cash flowMIRM Capital expendituresMIRM Stock buybacksMIRM Dividends paidMIRM Total assetsMIRM Total liabilitiesMIRM Shareholders’ equityMIRM overview →